Use of the Monoclonal Antibody Regdanvimab to Treat Patients Hospitalized with COVID-19: Real-World Data during the Delta Variant Predominance

Regdanvimab is the only monoclonal antibody available in Korea that targets severe acute respiratory syndrome coronavirus 2. We retrospectively evaluated the clinical characteristics of 374 adults hospitalized with coronavirus disease 2019 (COVID-19) who were treated with regdanvimab from September...

Descripción completa

Detalles Bibliográficos
Autores principales: Kwak, Yee Gyung, Song, Je Eun, Kang, Jieun, Kang, Jiyeon, Kang, Hyung Koo, Koo, Hyeon-Kyoung, Park, Hye Kyeong, Choi, Sang Bong, Lee, Hyuk Pyo, Lee, Myung Jin, Kim, Baek-Nam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society of Infectious Diseases; Korean Society for Antimicrobial Therapy; The Korean Society for AIDS 2022
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9840967/
https://www.ncbi.nlm.nih.gov/pubmed/36226346
http://dx.doi.org/10.3947/ic.2022.0103
Descripción
Sumario:Regdanvimab is the only monoclonal antibody available in Korea that targets severe acute respiratory syndrome coronavirus 2. We retrospectively evaluated the clinical characteristics of 374 adults hospitalized with coronavirus disease 2019 (COVID-19) who were treated with regdanvimab from September through December 2021. In total, 322 (86.1%) patients exhibited risk factors for disease progression. Most patients (91.4%) improved without additional treatment. No patient died or was transferred to intensive care. This study shows that regdanvimab prevented disease progression in high-risk patients with mild to moderate COVID-19 infections during Delta variant predominance.

Ejemplares similares